Ho Sung Cho
Director/Board Member presso BIOCOM
Profilo
Ho Sung Cho is on the board of BIOCOM and California Biomedical Innovation Alliance.
In the past Dr. Cho held the position of Team Leader at Exelixis, Inc., Associate Director-Protein Chemistry at Xencor, Inc., Chief Technology Officer at Ambrx, Inc., Vice President-Biotherapeutics at Celgene Corp., Staff Scientist at Lawrence Berkeley National Laboratory and Medicinal Chemist at Burroughs Wellcome.
Dr. Cho received a doctorate from the University of California.
Posizioni attive di Ho Sung Cho
Società | Posizione | Inizio |
---|---|---|
BIOCOM
BIOCOM Miscellaneous Commercial ServicesCommercial Services BIOCOM provides scientific and technological services. The firm focuses that positively influence the growth of the life science industry, including capital formation, public policy, workforce development and scientific discovery and development. The company was founded in 1995 and is headquartered in San Diego, CA. | Director/Board Member | 27/02/2017 |
California Biomedical Innovation Alliance
California Biomedical Innovation Alliance BiotechnologyHealth Technology California Biomedical Innovation Alliance provides biomedical advocacy and community services. The private company is based in South San Francisco, CA and has subsidiaries in United States. The CEO of the company is Sara Radcliffe. | Director/Board Member | 28/08/2017 |
Precedenti posizioni note di Ho Sung Cho
Società | Posizione | Fine |
---|---|---|
CELGENE | Corporate Officer/Principal | 01/11/2019 |
Boundless Bio, Inc.
Boundless Bio, Inc. BiotechnologyHealth Technology Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim on April 10, 2018 and is headquartered in San Diego, CA. | Director/Board Member | - |
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Director/Board Member | - |
Burroughs Wellcome | Corporate Officer/Principal | - |
Lawrence Berkeley National Laboratory
Lawrence Berkeley National Laboratory Miscellaneous Commercial ServicesCommercial Services Lawrence Berkeley National Laboratory engages on research of environmental studies, nanoscience, and quantitative biology, physics and nuclear energy. The lab is funded by the U.S. Department of Energy and managed by the University of California. It was founded in 1931 by Ernest Orlando Lawrence and is headquartered in Berkeley, CA. | Corporate Officer/Principal | - |
Formazione di Ho Sung Cho
University of California | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
EXELIXIS, INC. | Health Technology |
XENCOR, INC. | Health Technology |
Health Technology |
Aziende private | 7 |
---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Ambrx, Inc.
Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |
BIOCOM
BIOCOM Miscellaneous Commercial ServicesCommercial Services BIOCOM provides scientific and technological services. The firm focuses that positively influence the growth of the life science industry, including capital formation, public policy, workforce development and scientific discovery and development. The company was founded in 1995 and is headquartered in San Diego, CA. | Commercial Services |
Lawrence Berkeley National Laboratory
Lawrence Berkeley National Laboratory Miscellaneous Commercial ServicesCommercial Services Lawrence Berkeley National Laboratory engages on research of environmental studies, nanoscience, and quantitative biology, physics and nuclear energy. The lab is funded by the U.S. Department of Energy and managed by the University of California. It was founded in 1931 by Ernest Orlando Lawrence and is headquartered in Berkeley, CA. | Commercial Services |
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Health Technology |
Burroughs Wellcome | |
California Biomedical Innovation Alliance
California Biomedical Innovation Alliance BiotechnologyHealth Technology California Biomedical Innovation Alliance provides biomedical advocacy and community services. The private company is based in South San Francisco, CA and has subsidiaries in United States. The CEO of the company is Sara Radcliffe. | Health Technology |